Key result
Platelet inhibition levels on clopidogrel determine the risk of future ischemic events in patients with acute coronary syndromes.
Answers are grounded in this paper and cite their sources.
The degree of platelet inhibition on clopidogrel determines ischemic events in ACS patients, serving as a model for personalized antiplatelet therapy.
state of the art “...it was clearly demonstrated that the entity of platelet inhibition on clopidogrel is a determinant of ischemic ... events at follow-up of patients with acute coronary syndromes. Clopidogrel has been an excellent model to study personalized antiplatelet therapy.”
No takes yet. Share an insight, caveat, or question.
Marcucci et al. (2013) studied this question. Platelet inhibition levels on clopidogrel determine the risk of future ischemic events in patients with acute coronary syndromes.
Synapse has enriched 10 related papers. Consider them for comparative context: